ABT-869 CAS: 796967-16-3
MF: C21H18FN5O
MW: 375.4
A VEGF (Flk/Flt) and PDGFR inhibitor.

ABT-869 (CAS 796967-16-3)

  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 116ms
  • REVIEWS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Aplicação ABT-869 is a VEGF (Flk/Flt) and PDGFR inhibitor
Numero VAT: 796967-16-3
Peso Molecular: 375.4
Separar por Funcao: C21H18FN5O
Para uso em exclusivo em pesquisa. Não se destina a uso em diagnostico e tratamento.
* Refere-se a Certificado de Análise para data especifica de lotes (incluindo-se o conteúdo de agua).

ABT-869 is an ATP-competitive, multi-targeted RTK inhibitor that is completely effective against all members of the vascular endothelial growth factor (Flt/Flk) and PDGFR families (e.g., Flk-1 (KDR), Flt-1, Flt-3/Flk-2, Flt-4, c-Fms-CSF-1R, and c-KIT) demonstrating IC50 values ranging from 4-190 nM. ABT-869 shows little activity against unrelated RTKs, cytoplasmic tyrosine kinases, or Ser/Thr kinases (IC50 > 1 μM). ABT-869 inhibits proliferation in MV-4-11 and MOLM-13 cells (acute myeloid leukemia cell lines harboring RTK mutations; IC50 = 4 and 6 nM, respectively), inducing apoptosis as evidenced by an increased sub-G0/G1 phase cell population, caspase activation, and PARP cleavage. In murine xenograft models, as well as in a phase 1 clinical trial, ABT-869 demonstrated respectable efficacy in solid tumors including lung and hepatocellular carcinomas.


Referencias

1. Albert, D.H., et al. 2006. Mol. Cancer Ther. 5: 995-1006. PMID: 16648571
2. Shankar, D.B., et al. 2007. Blood. 109: 3400-3408. PMID: 17209055
3. Zhou, J., et al. 2009. J Hematol Oncol. 2: 33. PMID: 19642998

Estado físico :
Solid
envie :
Soluble in water (<1 mg/ml) at 25 °C, DMSO (~20 mg/ml), DMF (~20 mg/ml), 1:5 DMSO:PBS (pH 7.2) (~0.2 mg/ml), ethanol (5 mg/ml) at 25 °C, and methanol.
Manutencao :
Store at -20° C
Ponto de fusão :
180-183° C (dec.)
Ponto de fervura :
542.20° C at 760 mmHg (Predicted)
Densidade :
1.42 g/cm3 (Predicted)
Indice de produtos :
n20D 1.77 (Predicted)
IC50 :
human endothelial cells: IC50 = 0.2 nM; PDGFR-β: IC50 = 2 nM; KDR: IC50 = 4 nM; CSF-1R: IC50 = 3 nM; Flt1: IC50 = 3 nM; Flt3: IC50 = 4 nM; Vascular endothelial growth factor receptor 2: IC50 = 5 nM (human); Stem cell growth factor receptor: IC50 = 16 nM (human)
Valores de pK :
pKa: 13.30 (Predicted), pKb: 3.67 (Predicted)
Para uso em exclusivo em pesquisa. Não se destina a uso em diagnostico e tratamento.
PubChem CID :
Numero de FAX :
MFCD11840918
SMILES :
CC1=CC(=C(C=C1)F)NC(=O)NC2=CC=C(C=C2)C3=C4C(=CC=C3)NN=C4N

Baixar SDS (MSDS)

Certificado de Análise

É necessário o Adobe Acrobat Reader para visualizar corretamente,
imprimir e comentar os documentos PDF

  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 107ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 8ms
  • REVIEWS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;

A Santa Cruz Biotecnologia, Inc. é a líder mundial no desenvolvimento de produtos para o mercado de pesquisa biomédica. Ligue para nós ligação gratuita 1-800-457-3801..
Direito de Reprodução© 2007-2021 Santa Cruz Biotechnology, Inc. Todos os direitos reservados. "Santa Cruz Biotechnology", Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", "EZ Touch" são marcas registradas da Santa Cruz Biotechnology, Inc. Todas as marcas registradas são propriedade dos seus respectivos donos.